New combo pill shows promise for diabetes control

NCT ID NCT01026194

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new diabetes drug called teneligliptin (MP-513) combined with pioglitazone in 204 Japanese adults with type 2 diabetes. Participants took the combination for 12 weeks, then continued for up to a year. The main goal was to see if it lowered blood sugar levels (HbA1c) safely. Results showed better blood sugar control compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teneligliptin (a DPP-4 inhibitor) combined with pioglitazone (a thiazolidinedione)
What this could lead to: If successful, this combination could offer a new treatment option to help control blood sugar in people with type 2 diabetes.
What could go wrong: This is a completed Phase 3 trial, but results may not apply to all populations. The study only included Japanese patients, and long-term safety beyond 52 weeks is not assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Study site

Shinjukuku, Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.